Alvotech, a global name in the biosimilars sector, formed a licensing and supply partnership with Dr. Reddy’s Laboratories SA, a subsidiary of Dr. Reddy’s Laboratories. The partnership focuses on the commercialization of AVT03, Alvotech’s biosimilar candidate for denosumab, marketed as Prolia and Xgeva. The partnership leverages Dr. Reddy’s extensive commercial network and Alvotech’s expertise in biosimilar development for global markets.
Prolia and Xgeva are used to treat conditions such as osteoporosis in postmenopausal women and to prevent skeletal-related complications in adults with advanced cancers. As reported by businessline, as per the agreement, Alvotech will handle the development and manufacturing of AVT03, while Dr. Reddy’s will oversee the registration and commercialization efforts in the designated markets.
